A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars being spent by the pharma industry to shore up revenue streams amid a looming patent cliff will likely be well placed. The Swiss drugmaker reported a 12% drop in profits to $4.9bn compared with the same period in 2025. The profit tumble came alongside a decline in net sales, which reached $13.1bn, 1% shy of the $13.2bn from Q1 2025. Novartis blamed US generic erosion, which, the company added, more ...